| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 40.32 | 934 |
| Intrinsic value (DCF) | 3.38 | -13 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 64.15 | 1545 |
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a pioneering gene therapy company focused on developing innovative treatments for severe neurological diseases. Headquartered in Cambridge, Massachusetts, Voyager leverages its proprietary adeno-associated virus (AAV) gene therapy platform to target conditions such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and Friedreich's ataxia. The company's lead candidate, VY-AADC, is in Phase 1 clinical trials for Parkinson's, while its preclinical pipeline includes therapies for Alzheimer's, spinal muscular atrophy, and other neurodegenerative disorders. Voyager has strategic collaborations with industry leaders like Neurocrine Biosciences, Pfizer, and Novartis, enhancing its research and commercialization capabilities. Operating in the high-growth biotechnology sector, Voyager combines cutting-edge science with strategic partnerships to address unmet medical needs in neurology.
Voyager Therapeutics presents a high-risk, high-reward investment opportunity in the gene therapy space. The company's focus on neurological diseases—a market with significant unmet needs—positions it for long-term growth, especially if clinical trials succeed. However, its negative net income (-$65M in the latest period) and reliance on partnerships for funding highlight financial risks. The stock's beta of 0.95 suggests moderate volatility relative to the market. Investors should monitor clinical progress, partnership milestones, and cash burn ($71.4M cash on hand vs. $15.3M negative operating cash flow). Success in its Parkinson's program (VY-AADC) could be a major catalyst.
Voyager Therapeutics competes in the gene therapy sector by specializing in AAV-based treatments for neurological disorders—a niche with high barriers to entry due to technical complexity. Its competitive edge lies in its TRACER AAV capsid platform, which aims to improve targeting and delivery efficiency. Collaborations with Pfizer and Novartis validate its technology but also expose it to dependency risks. Compared to broader gene therapy players, Voyager's narrow focus on neurology differentiates it but limits diversification. The company faces stiff competition from firms with deeper pipelines or more advanced clinical programs (e.g., UniQure for Huntington's). Its modest market cap (~$162M) suggests it may be a takeover target for larger biotechs seeking neurology assets. Execution risk is high given its early-stage pipeline and reliance on external funding.